EpiEndo Pharmaceuticals Appoints Maria Bech as New Chief Executive Officer to Support Move into Clinical Development 3 years ago [#item_full_content] EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPDDateAugust 18, 2021In relation toSimilar postEpiEndo Pharmaceuticals Announces Launch of First-in-Human Clinical Trial of a Non-Antibiotic Macrolide for the Treatment of Chronic Inflammatory Airway DiseasesDateApril 13, 2021In relation toSimilar postAerie Pharmaceuticals Appoints Raj Kannan as Chief Executive OfficerDateDecember 16, 2021In relation toSimilar post
